« Return to News | Drug Sponsors

Adimab completes series F funding, begins expansion

Wednesday, April 4, 2012 10:32 AM

Adimab, a discovery company of fully human antibodies, has closed its over-subscribed Series F financing and acquired a research facility in Lebanon, N.H., where it plans to set up new headquarters.

The additional funds were raised entirely from existing investors, including Google Ventures, Polaris and SV Life Sciences. “These additional funds enhance our already strong balance sheet, allowing us to pursue several complementary opportunities more aggressively,” said Tillman Gerngross, CEO of Adimab.

With the new funding, Adimab plans to expand its platform to additional applications, such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.

“Our focus has always been on helping our partners develop better therapeutic antibodies,” ” said Errik Anderson, COO of Adimab. “Therefore, as we see attractive opportunities to acquire or develop additional capabilities we want to have excess capital to pursue them. Based on the strength of our current business we were able to raise capital under very attractive terms, which made this an easy decision.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.